TransCode Therapeutics, Inc

TransCodes lofty goal is delivering a cancer-free future for all cancer patients. Our core belief is that cancer can be overcome through the intelligent design and efficient delivery of targeted therapeutics. Our lead therapeutic candidate, TTX-MC138, targets microRNA-10b, or miRNA-10b, considered the master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and several others. Our other preclinical programs include two solid tumor programs, TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1, or PD-L1, and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. TransCode also has three cancer agnostic programs, TTX-RIGA, an...

Oncology,rna,diagnostics,nucleic acid therapeutics,orphan disease designation,metastasis,checkpoint inhibitor,pattern recognition receptor,mrna vaccine,and crispr

Transcode therapeutics, inc operates in the Biotechnology research industry.

Transcode therapeutics, inc's revenue is 11m - 100m

Transcode therapeutics, inc has 11 - 50 employees.